Carolyn D Britten

Summary

Affiliation: University of California
Country: USA

Publications

  1. pmc Transarterial chemoembolization plus or minus intravenous bevacizumab in the treatment of hepatocellular cancer: a pilot study
    Carolyn D Britten
    Division of Hematology Oncology, Department of Medicine, David Geffen School of Medicine at the University of California, Los Angeles, Santa Monica, CA 90404 2429, USA
    BMC Cancer 12:16. 2012
  2. ncbi request reprint Targeting ErbB receptor signaling: a pan-ErbB approach to cancer
    Carolyn D Britten
    Division of Hematology Oncology, Department of Medicine, David Geffen School of Medicine at University of California at Los Angeles, 10945 Le Conte Avenue, Los Angeles, CA 90095, USA
    Mol Cancer Ther 3:1335-42. 2004
  3. ncbi request reprint A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period
    Carolyn D Britten
    David Geffen School of Medicine at the University of California, Los Angeles 90095, USA
    Cancer Chemother Pharmacol 61:515-24. 2008
  4. doi request reprint A phase I/II trial of trastuzumab plus erlotinib in metastatic HER2-positive breast cancer: a dual ErbB targeted approach
    Carolyn D Britten
    Department of Medicine, University of California, Los Angeles, CA, USA
    Clin Breast Cancer 9:16-22. 2009
  5. doi request reprint Targeting vascular endothelial growth factor with the monoclonal antibody bevacizumab inhibits human hepatocellular carcinoma cells growing in an orthotopic mouse model
    Richard S Finn
    Department of Medicine, Division of Hematology Oncology, Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    Liver Int 29:284-90. 2009
  6. doi request reprint PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types
    Carolyn D Britten
    Division of Hematology Oncology, Department of Medicine, Hollings Cancer Center, Medical University of South Carolina, 96 Jonathan Lucas Street, Clinical Science Building, Suite 903, Charleston, SC 29425, USA
    Cancer Chemother Pharmacol 71:1395-409. 2013
  7. doi request reprint Dacomitinib (PF-00299804), an irreversible Pan-HER inhibitor, inhibits proliferation of HER2-amplified breast cancer cell lines resistant to trastuzumab and lapatinib
    Ondrej Kalous
    Department of Medicine, Division of Hematology Oncology, Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
    Mol Cancer Ther 11:1978-87. 2012
  8. doi request reprint Effect of the cytochrome P450 2C19 inhibitor omeprazole on the pharmacokinetics and safety profile of bortezomib in patients with advanced solid tumours, non-Hodgkin's lymphoma or multiple myeloma
    David I Quinn
    University of Southern California, Los Angeles, California, USA
    Clin Pharmacokinet 48:199-209. 2009
  9. doi request reprint Resection of thyroid cancer metastases to the sternum
    Jane Yanagawa
    Lung Cancer Research Program of the Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, Los Angeles, California, USA
    J Thorac Oncol 4:1022-5. 2009
  10. ncbi request reprint A phase I safety, tolerability, and pharmacokinetic study of enzastaurin combined with capecitabine in patients with advanced solid tumors
    D Ross Camidge
    Division of Medical Oncology, University of Colorado Cancer Center, Aurora, Colorado 80045, USA
    Anticancer Drugs 19:77-84. 2008

Collaborators

Detail Information

Publications16

  1. pmc Transarterial chemoembolization plus or minus intravenous bevacizumab in the treatment of hepatocellular cancer: a pilot study
    Carolyn D Britten
    Division of Hematology Oncology, Department of Medicine, David Geffen School of Medicine at the University of California, Los Angeles, Santa Monica, CA 90404 2429, USA
    BMC Cancer 12:16. 2012
    ..This pilot study examined whether intravenous (IV) bevacizumab, a monoclonal antibody against VEGF, could inhibit neovessel formation after TACE...
  2. ncbi request reprint Targeting ErbB receptor signaling: a pan-ErbB approach to cancer
    Carolyn D Britten
    Division of Hematology Oncology, Department of Medicine, David Geffen School of Medicine at University of California at Los Angeles, 10945 Le Conte Avenue, Los Angeles, CA 90095, USA
    Mol Cancer Ther 3:1335-42. 2004
    ..This minireview addresses the approaches being developed to concurrently inhibit multiple ErbB receptors...
  3. ncbi request reprint A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period
    Carolyn D Britten
    David Geffen School of Medicine at the University of California, Los Angeles 90095, USA
    Cancer Chemother Pharmacol 61:515-24. 2008
    ..This trial was performed to investigate the safety, tolerability, and pharmacokinetics of sunitinib 50 mg daily for 2 weeks followed by a 1-week off period (2/1 schedule)...
  4. doi request reprint A phase I/II trial of trastuzumab plus erlotinib in metastatic HER2-positive breast cancer: a dual ErbB targeted approach
    Carolyn D Britten
    Department of Medicine, University of California, Los Angeles, CA, USA
    Clin Breast Cancer 9:16-22. 2009
    ..This phase I/II trial was conducted to determine the toxicities, recommended dose, pharmacokinetics, and response rate of erlotinib plus trastuzumab in metastatic HER2+ breast cancer...
  5. doi request reprint Targeting vascular endothelial growth factor with the monoclonal antibody bevacizumab inhibits human hepatocellular carcinoma cells growing in an orthotopic mouse model
    Richard S Finn
    Department of Medicine, Division of Hematology Oncology, Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    Liver Int 29:284-90. 2009
    ..Bevacizumab, a humanized anti-VEGF monoclonal antibody, is currently being evaluated in the treatment of HCC. In addition, other novel anti-angiogenesis agents are being developed in HCC...
  6. doi request reprint PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types
    Carolyn D Britten
    Division of Hematology Oncology, Department of Medicine, Hollings Cancer Center, Medical University of South Carolina, 96 Jonathan Lucas Street, Clinical Science Building, Suite 903, Charleston, SC 29425, USA
    Cancer Chemother Pharmacol 71:1395-409. 2013
    ..The emerging clinical profile of PI3K and MEK inhibitor combinations, as reported in Phase I trials, will also be discussed...
  7. doi request reprint Dacomitinib (PF-00299804), an irreversible Pan-HER inhibitor, inhibits proliferation of HER2-amplified breast cancer cell lines resistant to trastuzumab and lapatinib
    Ondrej Kalous
    Department of Medicine, Division of Hematology Oncology, Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
    Mol Cancer Ther 11:1978-87. 2012
    ....
  8. doi request reprint Effect of the cytochrome P450 2C19 inhibitor omeprazole on the pharmacokinetics and safety profile of bortezomib in patients with advanced solid tumours, non-Hodgkin's lymphoma or multiple myeloma
    David I Quinn
    University of Southern California, Los Angeles, California, USA
    Clin Pharmacokinet 48:199-209. 2009
    ..The variability of bortezomib pharmacokinetics with CYP enzyme polymorphism was also investigated...
  9. doi request reprint Resection of thyroid cancer metastases to the sternum
    Jane Yanagawa
    Lung Cancer Research Program of the Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, Los Angeles, California, USA
    J Thorac Oncol 4:1022-5. 2009
    ..Overall, we demonstrate that radical resection of sternal metastases can be performed safely even in patients with poor prognosis to achieve palliation and potentiation of radioiodine therapy for concurrent metastases...
  10. ncbi request reprint A phase I safety, tolerability, and pharmacokinetic study of enzastaurin combined with capecitabine in patients with advanced solid tumors
    D Ross Camidge
    Division of Medical Oncology, University of Colorado Cancer Center, Aurora, Colorado 80045, USA
    Anticancer Drugs 19:77-84. 2008
    ..i.d.) on days 1-14 every 21 days. Further disease-directed studies are warranted, such as in malignancies in the treatment of which both capecitabine and inhibitors of angiogenesis have previously been benchmarked as being effective...
  11. ncbi request reprint Pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors: correlations with clinical characteristics and safety
    Feng Guo
    Department of Oncology, Pfizer Global Research and Development, 50 Pequot Avenue MS6025 A3238, New London, CT 06320, USA
    Cancer Chemother Pharmacol 62:97-109. 2008
    ....
  12. ncbi request reprint Development and validation of a drug activity biomarker that shows target inhibition in cancer patients receiving enzastaurin, a novel protein kinase C-beta inhibitor
    Lisa J Green
    Lilly Research Laboratories, Indianapolis, Indiana 46285, USA
    Clin Cancer Res 12:3408-15. 2006
    ....
  13. ncbi request reprint Clinical trial designs for targeted agents
    Brigette B Y Ma
    Department of Medical Oncology, Princess Margaret Hospital, University Health Network, 610 University Avenue, Toronto, ON M5G 2M9, Canada
    Hematol Oncol Clin North Am 16:1287-305. 2002
    ....
  14. ncbi request reprint First study of the safety, tolerability, and pharmacokinetics of CP-724,714 in patients with advanced malignant solid HER2-expressing tumors
    Pamela N Munster
    Department of Interdisciplinary Oncology, Experimental Therapeutics Program, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA
    Clin Cancer Res 13:1238-45. 2007
    ..To test the tolerability, safety, and recommended phase II dose of CP-724,714, a reversible, highly selective, oral HER2 tyrosine kinase inhibitor in patients with advanced solid tumor malignancies that express HER2...
  15. ncbi request reprint Phase I and pharmacologic study of the human DNA methyltransferase antisense oligodeoxynucleotide MG98 given as a 21-day continuous infusion every 4 weeks
    Alison J Davis
    National Cancer Institute, Canada
    Invest New Drugs 21:85-97. 2003
    ..This phase I study examined the toxicity and pharmacologic profile of MG98 administered as a continuous 21-day intravenous infusion every 4 weeks...
  16. ncbi request reprint A phase I study of pivaloyloxymethyl butyrate, a prodrug of the differentiating agent butyric acid, in patients with advanced solid malignancies
    Amita Patnaik
    Institute for Drug Development, Cancer Therapy and Research Center and The University of Texas Health Science Center at San Antonio, Texas 78229, USA
    Clin Cancer Res 8:2142-8. 2002
    ..Additional disease-directed clinical evaluations of AN-9 are necessary to establish the breadth of its antitumor activity and to assess its role as an effective differentiating agent...